These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33206021)

  • 21. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
    Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):237-250. PubMed ID: 38175140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 Jul; 24(7):647-653. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region.
    Alkhatib NS; Halloush S; Abraham I
    Expert Opin Biol Ther; 2023; 23(8):671-677. PubMed ID: 37493610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it.
    Mehr SR
    J Manag Care Spec Pharm; 2024 Jun; 30(6):600-603. PubMed ID: 38824633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic Drugs, Biosimilars, and Barriers to Entry.
    Shepherd JM
    Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.
    Simoens S; Jacobs I; Popovian R; Isakov L; Shane LG
    Pharmacoeconomics; 2017 Oct; 35(10):1047-1062. PubMed ID: 28660473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars and market access: a question of comparability and costs?
    Simoens S; Verbeken G; Huys I
    Target Oncol; 2012 Dec; 7(4):227-31. PubMed ID: 22249657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A place for biosimilars in the changing multiple sclerosis treatment landscape.
    Greenberg B; Giovannoni G
    Mult Scler Relat Disord; 2023 Sep; 77():104841. PubMed ID: 37467536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
    Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars in Belgium: a proposal for a more competitive market.
    Moorkens E; Vulto AG; Huys I
    Acta Clin Belg; 2021 Dec; 76(6):441-452. PubMed ID: 32400319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
    Chen BK; Yang YT; Bennett CL
    Drugs; 2018 Nov; 78(17):1777-1781. PubMed ID: 30446980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report.
    Moorkens E; Lacosta TB; Dawoud D; Inotai A; Janodia M; Tan CJ; Lim KK; Khatri N; Pereira CL; Simoens S
    Value Health; 2023 Aug; 26(8):1137-1144. PubMed ID: 37516531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.
    Kabir ER; Moreino SS; Sharif Siam MK
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
    Aladul MI; Fitzpatrick RW; Chapman SR
    Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Competition From Biosimilars Drives Price Reductions For Biologics In The French Single-Payer Health System.
    Robinson JC; Jarrion Q
    Health Aff (Millwood); 2021 Aug; 40(8):1190-1197. PubMed ID: 34339240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.